Ab1206 Pros and Clinical Activity in Patients With Systemic Sclerosis in Real Clinical Practice

Background: Although the utility of PROs (Patient-Reported Outcomes) has been demonstrated in various systemic autoimmune diseases, including Systemic Sclerosis, there appears to be a lack of data on some PROs in clinical practice for this disease. Objectives: Description of data derived from Patient-Reported Outcomes (PROs) in patients with Systemic Sclerosis (SSc) in real clinical practice. Methods: We conducted a single-center cross-sectional and descriptive study of patients diagnosed with SSc (ACR-EULAR 2013 criteria). Clinical evaluation of patients was conducted, and they systematically completed the Spanish version of the SF36 quality of life questionnaire, as well as the HAQ (Health Assessment Questionnaire) and CHFS (Cochin Hand Function Scale) questionnaires, which assess functional disability. In addition, Rodnan index, EUSTAR activity index, and Medsger severity scale were calculated. Results: A total of 42 patients with SSc were included, with a mean EUSTAR index score of 4.93 (1.45) points, a mean value of 4.8 on the Rodnan scale, and an average value of 4.05 on the Medsger scale. Regarding PROs, in the SF36 quality of life questionnaire, an average score of 51 (29.5) was obtained, and in the HAQ questionnaire, a mean score of 0.78 points, with 64% of patients scoring below 1. The average CHFS score was 14.29 out of a maximum of 90 points, with 71% of cases scoring below 18 points. We observed a statistically significant association between disease severity according to the Medsger scale and hand functional disability assessed through CHFS (P=0.03). A statistically significant association was also found between increased skin thickening according to the Rodnan index and a higher perception of quality of life by SF36 (P=0.03) and a higher perception of disability in both the CHFS scale (P=0.02) and the HAQ (P=0.03). Conclusion: An association was observed between the results obtained with PROs and the assessment of disease activity and severity in patients with Systemic Sclerosis. The role of PROs in the disease can assist us in the management of our patients. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.